{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059753","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.045843+00:00","generated_at":"2026-06-08T16:04:23.951681+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulcrum Therapeutics Q3 2023: net loss $24M, Phase 3 enrollment complete, cash runway extended into 2026","bullets":["Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.","FDA lifted clinical hold for pociredir in sickle cell disease; Phase 1b trial reinitiation underway with amended protocol.","Net loss of $24.0M for Q3 2023 vs $23.7M in prior-year quarter; R&D expenses increased to $18.2M.","Cash, cash equivalents, and marketable securities $257.1M as of Sep 30, 2023; cash runway extended into 2026.","Collaboration revenue $0.8M, down from $1.2M in Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059753","json":"https://secwatch.observer/filing/0000950170-23-059753.json","markdown":"https://secwatch.observer/filing/0000950170-23-059753.md","text":"https://secwatch.observer/filing/0000950170-23-059753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/0000950170-23-059753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/fulc-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:04:23.951681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87b543a3842c65af3158a04fecca6de75d581c1e","claim":"Fulcrum Therapeutics, Inc. reported third quarter of 2023 results: revenue $0.8 million, net income $24.0 million.","evidence_excerpt":"cash, cash equivalents, and marketable securities were $257.1 million, as compared to $202.9 million as of December 31, 2022. • Collaboration Revenue: Collaboration revenue was $0.8 million for the third quarter of 2023 as compared to $1.2 million for the third quarter of 2022. • R&D Expenses: Research and development expenses were $18.2 million for the third","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/0000950170-23-059753-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$0.8 million"},{"label":"Net income","value":"$24.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}